Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide for COVID-19 in Men
NCT04446429Completed
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of proxalutamide in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: COVID-19 Hospitalization at 30 days. Started Oct 2020; status: completed.
02
Drugs
proxalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04446429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446429.